196 related articles for article (PubMed ID: 17724350)
1. Raloxifene examined for breast cancer prevention.
Young D
Am J Health Syst Pharm; 2007 Sep; 64(17):1774. PubMed ID: 17724350
[No Abstract] [Full Text] [Related]
2. Raloxifene in breast cancer prevention.
Gennari L; Merlotti D; Paola VD; Nuti R
Expert Opin Drug Saf; 2008 May; 7(3):259-70. PubMed ID: 18462184
[TBL] [Abstract][Full Text] [Related]
3. STAR: first-year recruitment efforts set brisk pace for future.
CA Cancer J Clin; 2000; 50(5):271-2. PubMed ID: 11075236
[No Abstract] [Full Text] [Related]
4. Raloxifene vs tamoxifen.
Goldstein SR
JAMA; 2007 Jan; 297(3):263-4; author reply 264. PubMed ID: 17227974
[No Abstract] [Full Text] [Related]
5. [What do we think about selective estrogen receptor modulators?].
Cortet B
Rev Med Interne; 2001 Dec; 22(12):1173-6. PubMed ID: 11794886
[No Abstract] [Full Text] [Related]
6. Chemoprevention of breast cancer.
Zelnak AB; O'Regan RM
Curr Probl Cancer; 2004; 28(4):201-17. PubMed ID: 15318323
[No Abstract] [Full Text] [Related]
7. Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer.
Sporn MB
Clin Cancer Res; 2004 Aug; 10(16):5313-5. PubMed ID: 15328166
[No Abstract] [Full Text] [Related]
8. Medications for Primary Prevention of Breast Cancer.
Shieh Y; Tice JA
JAMA; 2020 Jul; 324(3):291-292. PubMed ID: 32692377
[No Abstract] [Full Text] [Related]
9. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
[TBL] [Abstract][Full Text] [Related]
10. Breast Cancer Risk-Reducing Medications.
Graham D; DiNome ML; Ganz PA
JAMA; 2020 Jul; 324(3):310. PubMed ID: 32692388
[No Abstract] [Full Text] [Related]
11. Recruitment of women into trials.
Benson JR
Lancet; 2002 Jan; 359(9301):164. PubMed ID: 11809281
[No Abstract] [Full Text] [Related]
12. Chemoprevention of breast cancer: recommendations and rationale.
U.S. Preventive Services Task Force
Ann Intern Med; 2002 Jul; 137(1):56-8. PubMed ID: 12093249
[No Abstract] [Full Text] [Related]
13. Breast cancer chemoprevention: current status and future directions.
Wickerham DL; Tan-Chiu E
Semin Oncol; 2001 Jun; 28(3):253-9. PubMed ID: 11402435
[TBL] [Abstract][Full Text] [Related]
14. Beyond raloxifene for the prevention of osteoporosis and breast cancer.
Jordan VC
Br J Pharmacol; 2007 Jan; 150(1):3-4. PubMed ID: 17115068
[TBL] [Abstract][Full Text] [Related]
15. Antiestrogens: clinical applications of pharmacology.
Jordan VC
J Soc Gynecol Investig; 2000; 7(1 Suppl):S47-8. PubMed ID: 10732329
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer prevention in high-risk women: searching for new options.
Nelson NJ
J Natl Cancer Inst; 2011 May; 103(9):710-1. PubMed ID: 21515834
[No Abstract] [Full Text] [Related]
17. Breast cancer chemoprevention.
Mamounas EP
Hematol Oncol Clin North Am; 2000 Jun; 14(3):727-38. PubMed ID: 11203331
[No Abstract] [Full Text] [Related]
18. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action.
Sporn MB; Dowsett SA; Mershon J; Bryant HU
Clin Ther; 2004 Jun; 26(6):830-40. PubMed ID: 15262454
[TBL] [Abstract][Full Text] [Related]
19. Role of antiestrogens and aromatase inhibitors in breast cancer treatment.
Bentrem DJ; Jordan VC
Curr Opin Obstet Gynecol; 2002 Feb; 14(1):5-12. PubMed ID: 11801870
[TBL] [Abstract][Full Text] [Related]
20. Tipping the balance for the primary prevention of breast cancer.
Vogel VG
J Natl Cancer Inst; 2010 Nov; 102(22):1683-5. PubMed ID: 21051657
[No Abstract] [Full Text] [Related]
[Next] [New Search]
